Industries > Pharma > Global Graft versus Host Disease (GVHD) Market 2019-2029

Global Graft versus Host Disease (GVHD) Market 2019-2029

Acute, Chronic and Prophylaxis GVHD

PAGES: 162
PRODUCT CODE: PHA0384
SUBMARKET: Therapeutic Drugs

WOOCS 2.2.1
DOWNLOAD FREE SAMPLE
SKU: PHA0384 Categories: , Tags: , , ,

The global graft versus host disease market is expected to grow at a CAGR of 7% from 2016-2021 and CAGR of 3% from 2019-2029. The market is expected to grow at a CAGR of 6% from 2016 to 2027. The market is estimated at $0.36bn in 2016, $0.51bn in 2021, and $0.64bn in 2026.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 162-page report you will receive 62 tables and 76 figures – all unavailable elsewhere.

The 162-page report provides clear detailed insight into the Graft versus Host Disease market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

• Revenue and growth forecasts to 2027 for the global GVHD market

• Revenue and growth forecasts to 2027 for the leading countries

• GVHD patient number forecast to 2027 per leading country, segmented into total allogenic cases, first allogenic cases, acute GVHD and chronic GVHD

• Revenue and growth forecasts to 2027 for the leading segments of the GVHD market by treatment type

• Revenue and growth forecasts to 2027 for the leading drugs in the GVHD market.

Global Graft versus Host Disease (GVHD) Market 2017-2027

Individual revenue forecasts to 2027 by treatment type:
• Prophylaxis GVHD
• Chronic GVHD
• Acute GVHD

Individual revenue forecasts to 2027 by product:

• Corticosteroids
– Methylprednisolone
– Budenofalk (effeverscent)

• ATG therapies
– Available ATG therapy (Thymoglobulin)
– Atege-Fresenius

• IL2Rα (CD25) inhibitors
– Simulect (Basiliximab)
– Leukotac (inolimomab)

• TNFα inhibitors
– Remicade (Infliximab)
– Enbrel (Etanercept)
– Co-stimulatory blockers
– Orencia (abatacept)
– Nulojix (belatacept)

• Other biologics
– Lemtrada (Alemtuzumab)
– Rituxan/MabThera (rituximab)
– Begedina (bt/9 anti-CD26)

• Calcineurin inhibitors
– Cyclosporine

• mTOR inhibitors
– Rapamune (sirolimus)
– Certican (everolimus)

• SOT therapies
– CellCept/Myfortic (mycophenolate mofetil)
– Prograf (tacrolimus)

• Anti-neoplastic therapies
– Velcade (bortezomib)
– Gleevec (imatinib)
– Methrotrexate
– Nipent (pentostatin)
– Cyclophosphamide

• Stem Cell Treatments
– In situ preparations of mesenchymal cells
– Prochymal (remestemcel-L)

• Extracorporeal Photophoresis
– Uvadex (Therakos)

Individual revenue forecasts to 2027 by country, further segmented by treatment type and by product:
• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

GVHD patient number forecasts to 2027 per leading country, segmented into:
• total allogenic cases
• first allogenic cases
• acute GVHD
• chronic GVHD

Visiongain’s study is intended for anyone requiring commercial analyses for the GVHD market. You find data, trends and predictions.

Buy our report today Global Graft versus Host Disease (GVHD) Market 2019-2029: Acute, Chronic and Prophylaxis GVHD.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Global Graft versus Host Disease (GVHD) Market 2019-2029

    Download sample pages

    Complete the form below to download your free sample pages for Global Graft versus Host Disease (GVHD) Market 2019-2029

      Latest Pharma news

      Visiongain Publishes Allergy Immunotherapy Market Report 2023-2033

      The global Allergy Immunotherapy market is projected to grow at a CAGR of 7.6% by 2033

      31 May 2023

      READ

      Visiongain Publishes AI-based Clinical Trial Solution Providers Market Report 2023-2033

      The global AI-based Clinical Trial Solution Providers market was valued at US$1,232.0 million in 2022 and is projected to grow at a CAGR of 23.3% during the forecast period 2023-2033.

      26 May 2023

      READ

      Visiongain Publishes Vaccine Contract Manufacturing Market Report 2023-2033

      The global Vaccine Contract Manufacturing Market is projected to grow at a CAGR of 13.2% by 2033

      24 May 2023

      READ

      Visiongain Publishes Cell & Gene Therapy Cold Chain Logistics Market Report 2023-2033

      The global Cell & Gene Therapy Cold Chain Logistics market is projected to grow at a CAGR of 15% by 2033

      23 May 2023

      READ